Business

NeuroScientific widens chronic bowel disease stem cell therapy program

NeuroScientific Biopharmaceuticals dosed a fourth Crohn’s patient with its StemSmart therapy ahead of phase 2 trials for its novel treatment of the debilitating bowel disease.

Business / Companies

Brisbane Times – Business

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:Business